All In Biotech

Drug Trial Radar · NCT03383042

Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy Male Subjects

A Randomized, Open-label, Placebo- and Active- Controlled, Single and Multiple Ascending Dose Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy Male Subjects

Last checked: Nov 19, 2026Latest source record: Apr 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 115 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

115

Actual

Start

Dec 22, 2017

Primary completion

Nov 23, 2018

Study completion Apr 5, 2019

Sponsor

Lead sponsor
Jeil Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Dec 26, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 19 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Clinical trial to investigate the safety, tolerability and pharmacokinetics and pharmacodynamics of JP-1366 oral administration in healthy male subjects

Conditions

  • Anti-Ulcer Agents

Interventions

  • Cohort 1 (JP-1366 A mg)Drug

    Drug: JP-1366 A mg or JP-1366 Placebo or Esomeprazole 40 mg

  • Cohort 2 (JP-1366 B mg)Drug

    Drug: JP-1366 B mg or JP-1366 Placebo or Esomeprazole 40 mg

  • Cohort 3 (JP-1366 C mg)Drug

    Drug: JP-1366 C mg or JP-1366 Placebo or Esomeprazole 40 mg

  • Cohort 4 (JP-1366 D mg)Drug

    Drug: JP-1366 D mg or JP-1366 Placebo or Esomeprazole 40 mg

  • Cohort 5 (JP-1366 E mg)Drug

    Drug: JP-1366 E mg or JP-1366 Placebo or Esomeprazole 40 mg

  • Cohort 6 (JP-1366 F mg)Drug

    Drug: JP-1366 F mg or JP-1366 Placebo or Esomeprazole 40 mg

  • Cohort 7 (JP-1366 G mg)Drug

    Drug: JP-1366 G mg or JP-1366 Placebo or Esomeprazole 40 mg

  • Cohort 8 (JP-1366 H mg)Drug

    Drug: JP-1366 H mg or JP-1366 Placebo or Esomeprazole 40 mg

  • Cohort 9 (JP-1366 I mg)Drug

    Drug: JP-1366 I mg or JP-1366 Placebo or Esomeprazole 40 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose
  2. AUClastTime frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose
  3. AUCinfTime frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose
  4. tmaxTime frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose
  5. t1/2Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose
  6. Cmax,ssTime frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose
  7. Cmin,ssTime frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose
  8. Cav,ssTime frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose
  9. AUCτTime frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose
  10. tmax,ssTime frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose
  11. t1/2Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose
  12. Percentage of total time that the intragastric pH was above 4Time frame: 0-24 hours(Day -1), 0-24 hours(Day 1)
  13. Percentage of total time that the intragastric pH was above 4Time frame: 0-24 hours (Day -1), 0-24 hours (Day 1), 0-24 hours (Day 7)
  14. Serum gastrin concentrationTime frame: Pre-dose, 2, 4, 6, 8, 12h post-dose, Day 1 pre-dose, 2, 4, 6, 8, 12, 24, 48h post-dose
  15. Serum gastrin concentrationTime frame: Pre-dose, 2, 4, 6, 8, 12h post-dose, Day 1 pre-dose, 2, 4, 6, 8, 12, 24h post-dose, Day 4 pre-dose, Day 6 pre-dose, Day 7 pre-dose, 2, 4, 6, 8, 12, 24, 48h post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospital(SNUH)

    Seoul, Jongno-Gu, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.